Oncolytics Biotech (TSE:ONC) Shares Down 1.6% – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC)’s stock price traded down 1.6% on Thursday . The company traded as low as C$1.18 and last traded at C$1.20. 123,141 shares were traded during trading, an increase of 72% from the average session volume of 71,561 shares. The stock had previously closed at C$1.22.

Analysts Set New Price Targets

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Stock Down 1.6 %

The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86. The company has a market cap of C$92.23 million, a price-to-earnings ratio of -3.16 and a beta of 1.35. The firm has a 50-day moving average price of C$1.52 and a 200 day moving average price of C$1.42.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.